source
- Pathos AI secures $237M Series E funding at $3B valuation, partners with Bristol Myers on neurosciencePathos AI, an AI-focused biotech based in New York, announced it has closed a Series E financing round raising $237 million. The round values the company at $3 billion, reflecting investor confide…
- AI drug developer Pathos secures $237 million Series E, valuation hits $3 billionPathos announced a $237 million Series E round led by Bristol Myers Squibb, lifting its valuation to about $3 billion. The funding will support expansion beyond oncology into neurology, leveraging…